Date: 2015-12-17
Type of information: Licensing agreement
Compound: Cymerus™ therapeutic mesenchymal stem cell (MSC) technology.
Company: apceth (Germany) Cynata Therapeutics (Australia)
Therapeutic area: Cancer - Oncology
Type agreement: licencing
Action mechanism: stem cell therapy
Disease:
Details:
- • On December 17, 2015, Cynata Therapeutics announced that it has signed a Letter of Intent (LOI) regarding a future option and license agreement with apceth, a leading company using modified MSCs to treat cancer and other life-altering conditions. The LOI lays the path for a commercial transaction between Cynata and apceth pursuant to which,
Cynata would grant to apceth certain rights, to develop and commercialise Cynata’s proprietary Cymerus™ therapeutic mesenchymal stem cell (MSC) technology. During the coming weeks, under the LOI, the management teams of apceth and Cynata will evaluate and define the key terms of an option and license agreement.
Financial terms:
Latest news:
Is general: Yes
